Nonclinical safety evaluation of biotechnologically derived pharmaceuticals (Q33955695)

30 July 2017

1 reference

title

Nonclinical safety evaluation of biotechnologically derived pharmaceuticals (English)

1 reference

30 July 2017

0 references

Dempster AM

1

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Biotechnology Annual Review

30 July 2017

published in

1 reference

30 July 2017

volume

5

1 reference

30 July 2017

page(s)

221-258

1 reference

Issues with biotechnology products in toxicologic pathology

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Safety evaluation of biological and biotechnology-derived medicines

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Safety evaluation of biotechnology products

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Erythropoietin increases blood pressure in normotensive and hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Direct vasopressor effects of erythropoietin in genetically hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Interleukin-1: biological effects in human hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The Therapeutic Potential of Interleukin-1 and Tumor Necrosis Factor on Hematopoietic Stem Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Drug delivery systems and routes of administration of peptide and protein drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The role of pharmacokinetics in the development of biotechnologically derived agents

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Clinical toxicity of the interferons.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Common pathways of interferon and hormonal action

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The preclinical development of Roferon-A.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Validation of a heterologous radioimmunoassay for insulin-like growth factor-I in bovine serum

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

A specific growth hormone-binding protein in human plasma: initial characterization

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Identification and characterization of specific binding proteins for growth hormone in normal human sera

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Insulin-like growth factor-binding proteins (IGFBPs): more than just 1, 2, 3

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

From the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

From the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

The pharmacology and toxicology of the interferons: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Clinical toxicity of cytokines used as haemopoietic growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Clinical toxicity of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Antisense oligonucleotides: towards clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Commentary: regulatory issues affecting oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Oligonucleotide sequences required for natural killer cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Safety of airway gene transfer with Ad2/CFTR2: aerosol administration in the nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Safety aspects of gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

Highly preferred targets for retrovirus integration

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

What about those monkeys that got T-cell lymphoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905037-7

7 January 2021

10.1016/S1387-2656(00)05037-7

Identifiers

DOI

1 reference

30 July 2017

1 reference